Norepinephine transporter inhibitors and their therapeutic potential
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The norepinephrine transporter (NET) is located in the plasma membrane of noradrenergic neurons, where it functions to take up synaptically released norepinephrine (NE). The NET thus serves as the primary mechanism for the inactivation of noradrenergic signaling. Some potent and selective or mixed NET inhibitors (e.g., reboxetine and atomoxetine) have been successfully developed to treat a variety of mental disorders such as depression and attention deficit hyperactivity disorder (ADHD). However, to date, only a very limited number of NET-selective inhibitors are available. New potent and selective NET inhibitors may find application in the treatment of mental disorders or in PET imaging, and may enhance our basic understanding of these illnesses. In the present review, both previously reported and newly designed NET inhibitors, as well as their therapeutic and imaging potential, will be discussed. Two types of molecules, the conformationally constrained tropanes and the piperidine-based nocaine/modafinil hybrid ligands, represent new leads and provide good opportunities for discovering novel potent and selective NET inhibitors that are useful as therapies and imaging agents for the NET.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Narcolepsy in orexin Knockout Mice
Chemelli, R. M., Willie, J. T., Sinton, C. M., Elmquist, J. K., Scammell, T., Lee, C., Richardson, J. A., Williams, S. C., Xiong, Y., Kisanuki, Y., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)81973-x · Cited by 3,095 · cited 1×
“Modafinil’s mode of action is complex and still uncertain, although studies suggest that it increases wakefulness by activating α1-adrenergic transmission (51) or hypothalamic cells that contain the peptide hypocretin (52), or that it may work by modulating GABAergic tone (53).”
BackgroundBymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123
Expression cloning of a cocaine-and antidepressant-sensitive human noradrenaline transporter
Pacholczyk, T., Blakely, R. D., & Amara, S. G. (1991) · Nature · doi:10.1038/350350a0 · Cited by 933 · cited 1×
“The NET thus serves as the primary mechanism for the inactivation of noradrenergic signaling (22-24).”
BackgroundAtomoxetine in adults with ADHD: two randomized, placebo-controlled studies
Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. A., Allen, A. J., Kelsey, D., Wernicke, J., Dietrich, A., & Milton, D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01671-2 · Cited by 790
Stahl, S. M., Pradko, J., Haight, B. R., Modell, J. G., Rockett, C. B., & Learned-Coughlin, S. (2004) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v06n0403 · Cited by 495 · cited 8×
“Einarson TR, Addis A, Mittmann N, Iskedjian M. Meta-analysis of venlafaxine, SSRIs and TCAs in the treatment of major depressive disorder.”
BackgroundInfluential
Cited by
SLC6 Neurotransmitter Transporters: Structure, Function, and Regulation
Kristensen, A. S., Andersen, J., Jørgensen, T. N., Sørensen, L., Eriksen, J., Loland, C. J., Strømgaard, K., & Gether, U. (2011) · Pharmacological Reviews · doi:10.1124/pr.108.000869 · Cited by 864
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Samuels, E., & Szabadi, E. (2008) · Current Neuropharmacology · doi:10.2174/157015908785777193 · Cited by 454
Norepinephrine: The redheaded stepchild of Parkinson's disease
Rommelfanger, K. S., & Weinshenker, D. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.01.036 · Cited by 255
Deep contrastive learning enables genome-wide virtual screening
Jia, Y., Gao, B., Tan, J., Zheng, J., Hong, X., Zhu, W., Tan, H., Xiao, Y., Tan, L., Cai, H., et al. (2026) · Science · doi:10.1126/science.ads9530 · Cited by 66
Metadata
- Authors
- Zhou, J.
- Venue
- Drugs of the Future
- Publisher
- Portico
- Published
- 2004
- Volume
- 29
- Issue
- 12
- Pages
- 1235
- ISSN
- 0377-8282 (ISSN-L)
- 2013-0368
- OpenAlex
- W2067330891
- Cited by
- 134
- References
- 5
- FWCI
- 1.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Norepinephine transporter inhibitors and their therapeutic potential. https://app.cochat.ai/papers/10.1358/dof.2004.029.12.855246
- The paper
- Zhou, J. (2004). Norepinephine transporter inhibitors and their therapeutic potential. Drugs of the Future. https://doi.org/10.1358/dof.2004.029.12.855246
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.